Scientists create an scRNA-seq atlas of the multiple myeloma immune microenvironment across disease stages
Multiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...
clinicaltrialsarena on MSN18h
GSK reports positive outcomes from Phase III multiple myeloma treatment trial
GSK has announced positive headline outcomes from a Phase III trial of Blenrep with bortezomib and dexamethasone for multiple ...
Targeted Oncology6h
Usmani Projects a Future of CAR T in Community for Myeloma and Other Cancers
During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed quality of life and the future with CAR ...
News Medical on MSN1d
Interactive atlas unveils immune changes in multiple myeloma
Multiple Myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...
Military.com3d
VA Set to Add Leukemia, Multiple Myeloma to List of Conditions Linked to Burn Pits
The department used its new system for determining whether a condition is service-connected to give affected veterans access ...
Targeted Oncology10h
Study Launches of QXL138AM in Multiple Myeloma and Solid Tumors
Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...
BioSpace1d
GSK Builds Case for Blenrep with Multiple Myeloma OS Data That Bests J&J’s Darzalex
GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...
Frontiers21h
Understanding Adverse Effect in Myeloma Patients treated with T Cell Redirecting Immunotherapies
Multiple Myeloma, a cancer of the plasma cells in the bone marrow, is the third most common blood cancer in Europe. Despite recent advanced in treatment that has increased survival, it is still an ...
The American Journal of Managed Care7h
Elevating Myeloma Care Amidst Complex Treatment Choices
Don M. Benson, MD, PhD, has cared for patients at James Cancer Hospital in Ohio for 22 years, where he and his team see approximately 10,000 patient visits each year.
Healthcare Asia on MSN1d
Pharmaceutical firms eye multiple myeloma amidst rising incidence rates
The increase has been faster in women since 2000. The rising incidence of multiple myeloma (MM), particularly in relapsed and ...